Abstract
Understanding changes in human mobility in the early stages of the COVID-19 pandemic is crucial for assessing the impacts of travel restrictions designed to reduce disease spread. Here, relying on data from mainland China, we investigated the spatio-temporal characteristics of human mobility between 1st January and 1st March 2020 and discussed their public health implications. An outbound travel surge from Wuhan before travel restrictions were implemented was also observed across China due to the Lunar New Year, indicating that holiday travel may have played a larger role in mobility changes compared to impending travel restrictions. Holiday travel also shifted healthcare pressure related to COVID-19 towards locations with lower access to care. Network analyses showed no sign of major changes in the transportation network after Lunar New Year. Changes observed were temporary and have not yet led to structural reorganisation of the transportation network at the time of this study.
One sentence summary: Understanding travel before, during, and after the introduction of travel restrictions in China in response to the COVID-19 Pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors acknowledge funding as follows: HG: funding from the Department of Health and Social Care using UK Aid funding and managed by the NIHR under grant (ITCRZ 03010). YL: Bill and Melinda Gates Foundation (INV-003174), NIHR (16/137/109), European Commission (101003688); CABP: BMGF (OPP1184344) & DFID / Wellcome (ref. 221303/Z/20/Z); CIJ: Global Challenges Research Fund (GCRF) project ‘RECAP’ managed through RCUK and ESRC (ES/P010873/1); BQ This research was partly funded by the National Institute for Health Research (NIHR) (16/137/109) using UK Aid from the UK Government to support global health research; CD: NIHR (16/137/109); and RME: HDR UK (grant: MR/S003975/1), MRC (grant: MC_PC 19065). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. The working group acknowledges the following funding: QJL: Medical Research Council London Intercollegiate Doctoral Training Program studentship (grant no. MR/N013638/1), AG: Global Challenges Research Fund (GCRF) for the project ‘RECAP’ managed through RCUK and ESRC (ES/P010873/1), MA: Bill and Melinda Gates Foundation (OPP1191821), RL: Royal Society Dorothy Hodgkin Fellowship, KO'R: Bill and Melinda Gates Foundation (OPP1191821), MQ: European Research Council Starting Grant (Action Number #757699), JH: Wellcome Trust (grant: 210758/Z/18/Z), GMK: UK Medical Research Council (grant: MR/P014658/1), TJ: RCUK/ESRC (grant: ES/P010873/1); UK PH RST; NIHR HPRU Modelling Methodology, PK: This research was partly funded by the Royal Society under award RP\EA\180004, European Commission (101003688), Bill & Melinda Gates Foundation (INV-003174), SRP: Bill and Melinda Gates Foundation (OPP1180644), EMR: Medical Research Council London Intercollegiate Doctoral Training Program studentship (grant MR/N013638/1), SFlasche: Wellcome Trust (grant: 208812/Z/17/Z), AJK: Wellcome Trust (grant: 206250/Z/17/Z), SA: Wellcome Trust (grant: 210758/Z/18/Z), FYS: NIHR EPIC grant (16/137/109), AE: The Nakajima Foundation; The Alan Turing Institute, GM: NTD Modelling Consortium by the Bill and Melinda Gates Foundation (OPP1184344), JDM: Wellcome Trust (grant: 210758/Z/18/Z), SRM: Wellcome Trust (grant: 210758/Z/18/Z), NIB: Wellcome Trust (grant: 210758/Z/18/Z), WJE: European Commission (101003688), NGD: (NIHR: Health Protection Research Unit for Modelling Methodology HPRU-2012-10096), KP: Gates (INV-003174), European Commission (101003688), CJVA: European Research Council Starting Grant (Action Number #757688), ESN: Gates (OPP1183986), RMGJH: European Research Council Starting Grant (Action Number #757699), JCE: European Research Council Starting Grant (Action Number #757699), KvZ: KvZ, is supported by the UK Government Department for International Development (DFID)/Wellcome Trust Epidemic Preparedness Coronavirus research programme (ref. 221303/Z/20/Z), and Elrha’s Research for Health in Humanitarian Crises (R2HC) Programme, which aims to improve health outcomes by strengthening the evidence base for public health interventions in humanitarian crises. The R2HC programme is funded by the UK Government (DFID), the Wellcome Trust, and the UK National Institute for Health Research (NIHR), KEA: European Research Council Starting Grant (Action Number #757688), AR: NIHR (grant: PR-OD-1017-20002), SFunk: Wellcome Trust (grant: 210758/Z/18/Z), MJ: Gates (INV-003174), NIHR (16/137/109), European Commission (101003688), SC: Wellcome Trust (grant: 208812/Z/17/Z), TWR: Wellcome Trust (grant: 206250/Z/17/Z).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used were publicly available and can be found at the references. Code is publicly available in a Github repository.
